Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fordras is a Swiss pharmaceutical company specializing in the development and production of high-quality enzymes and active pharmaceutical ingredients (APIs). The company is globally recognized as a leading producer of Lysozyme Hydrochloride, an enzyme with significant antibacterial and antiviral properties used in both the pharmaceutical and food industries. Beyond Lysozyme, Fordras offers a range of products including Lactoferrin and other specialized proteins. Headquartered in Lugano, the company maintains rigorous GMP standards to supply the global healthcare market. Their expertise lies in extraction and purification technologies for naturally derived substances. The company serves a diverse clientele across the pharmaceutical, nutraceutical, and food sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fordras.